{'fraction_non_alphanumeric': 0.03601895734597156, 'fraction_numerical': 0.002843601895734597, 'mean_word_length': 5.857142857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hollow nanocapsules of NiFe hydroxides to enable doxorubicin delivery and combinational tumour therapy.

In this study, fine hollow nanocapsules, consisting of NiFe hydroxides (denoted as H-NiFe(OH)x), are designed and synthesized for the delivery of an anticancer drug (Doxorubicin, DOX) and tumour depletion. Owing to its fascinating characteristics of "Fe2+ preservation and regeneration", H-NiFe(OH)x presents considerable Fenton activity for hydroxyl radical (˙OH) induction. Efficient delivery of DOX is ensured due to its hollow microstructure, and a typical pH-responsive drug release is enabled. More importantly, the intracellular DOX, in addition to its intrinsic antitumour properties, induces extra exogenous H2O2 which favors the production of ˙OH by H-NiFe(OH)x in tumour cells. In consequence, remarkable in vitro and in vivo antitumour properties are successfully achieved. This drug delivery system is particularly inspirational to further studies in the exploration of intelligent therapeutic platforms for combinational tumour therapy.